

# Benjamin A Teply

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5920828/publications.pdf>

Version: 2024-02-01

43  
papers

4,825  
citations

430843

18  
h-index

345203

36  
g-index

44  
all docs

44  
docs citations

44  
times ranked

7405  
citing authors

#	ARTICLE	IF	CITATIONS
1	Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy <i>in vivo</i> . Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 6315-6320.	7.1	1,595
2	Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery. Biomaterials, 2007, 28, 869-876.	11.4	1,151
3	Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 2586-2591.	7.1	649
4	NCCN Guidelines Insights: Prostate Cancer, Version 1.2021. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 134-143.	4.9	299
5	Microfluidic System for Studying the Interaction of Nanoparticles and Microparticles with Cells. Analytical Chemistry, 2005, 77, 5453-5459.	6.5	159
6	Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study. Lancet Oncology, The, 2018, 19, 76-86.	10.7	149
7	Engineering of Targeted Nanoparticles for Cancer Therapy Using Internalizing Aptamers Isolated by Cell-Uptake Selection. ACS Nano, 2012, 6, 696-704.	14.6	148
8	Magnetically Responsive Polymeric Microparticles for Oral Delivery of Protein Drugs. Pharmaceutical Research, 2006, 23, 557-564.	3.5	122
9	Collagen composite hydrogels for vocal fold lamina propria restoration. Biomaterials, 2006, 27, 1104-1109.	11.4	119
10	The use of charge-coupled polymeric microparticles and micromagnets for modulating the bioavailability of orally delivered macromolecules. Biomaterials, 2008, 29, 1216-1223.	11.4	63
11	A Multicohort Open-label Phase II Trial of Bipolar Androgen Therapy in Men with Metastatic Castration-resistant Prostate Cancer (RESTORE): A Comparison of Post-abiraterone Versus Post-enzalutamide Cohorts. European Urology, 2021, 79, 692-699.	1.9	49
12	Sildenafil Potentiates the Therapeutic Efficacy of Docetaxel in Advanced Prostate Cancer by Stimulating NO-cGMP Signaling. Clinical Cancer Research, 2020, 26, 5720-5734.	7.0	28
13	Effect of Cisplatin and Gemcitabine With or Without Berzosertib in Patients With Advanced Urothelial Carcinoma. JAMA Oncology, 2021, 7, 1536.	7.1	28
14	Treatment strategies for DNA repair-deficient prostate cancer. Expert Review of Clinical Pharmacology, 2017, 10, 889-898.	3.1	26
15	Extreme Response to High-dose Testosterone in BRCA2- and ATM-mutated Prostate Cancer. European Urology, 2017, 71, 499.	1.9	26
16	Randomized Phase III Trial of Gemcitabine and Cisplatin With Bevacizumab or Placebo in Patients With Advanced Urothelial Carcinoma: Results of CALGB 90601 (Alliance). Journal of Clinical Oncology, 2021, 39, 2486-2496.	1.6	26
17	Cardiovascular risks and toxicity - The Achilles heel of androgen deprivation therapy in prostate cancer patients. Biochimica Et Biophysica Acta: Reviews on Cancer, 2020, 1874, 188383.	7.4	23
18	Impact of Proton Pump Inhibitor Use on the Effectiveness of Immune Checkpoint Inhibitors in Advanced Cancer Patients. Annals of Pharmacotherapy, 2022, 56, 377-386.	1.9	21

#	ARTICLE	IF	CITATIONS
19	Chemotherapy options in castration-resistant prostate cancer. <i>Indian Journal of Urology</i> , 2016, 32, 262.	0.6	19
20	Tumor- and osteoclast-derived NRP2 in prostate cancer bone metastases. <i>Bone Research</i> , 2021, 9, 24.	11.4	17
21	Novel mechanism-based therapeutics for androgen axis blockade in castration-resistant prostate cancer. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2016, 23, 279-290.	2.3	16
22	Novel treatment strategy for refractory hemorrhagic cystitis following radiation treatment of genitourinary cancer. <i>Lasers in Medical Science</i> , 2012, 27, 1099-1102.	2.1	14
23	Systemic therapy for bladder cancer – a medical oncologist’s perspective. <i>Journal of Solid Tumors</i> , 2014, 4, 25-35.	0.1	14
24	Biomarkers for Treatment Response in Advanced Prostate Cancer. <i>Cancers</i> , 2021, 13, 5723.	3.7	14
25	Impact of Performance Status on Response and Survival Among Patients Receiving Checkpoint Inhibitors for Advanced Solid Tumors. <i>JCO Oncology Practice</i> , 2022, 18, e175-e182.	2.9	12
26	Impact of performance status on response and survival among patients receiving checkpoint inhibitors for advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2020, 38, 12028-12028.	1.6	6
27	Targeting resistant prostate cancer with ATR and PARP inhibition (TRAP trial): A phase II study.. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS254-TPS254.	1.6	6
28	Development of bullous pemphigoid following radiation therapy combined with nivolumab for renal cell carcinoma. <i>Medicine (United States)</i> , 2021, 100, e28199.	1.0	6
29	Nanoparticle-Aptamer Bioconjugates for Targeted Antineoplastic Drug Delivery. <i>American Journal of Drug Delivery</i> , 2006, 4, 123-130.	0.6	4
30	Targeting treatment options for castration-resistant prostate cancer. <i>American Journal of Clinical and Experimental Urology</i> , 2021, 9, 101-120.	0.4	4
31	Risk of development of visceral metastases subsequent to abiraterone vs placebo: An analysis of mode of radiographic progression in COU-AA-302. <i>Prostate</i> , 2019, 79, 929-933.	2.3	3
32	Current Management of Refractory Germ Cell Tumors. <i>Current Oncology Reports</i> , 2021, 23, 101.	4.0	2
33	A randomized phase II study comparing cisplatin and gemcitabine with or without berzosertib in patients with advanced urothelial carcinoma.. <i>Journal of Clinical Oncology</i> , 2021, 39, 4507-4507.	1.6	1
34	Patterns of metastatic disease progression after treatment with first-line enzalutamide or abiraterone in castration-resistant prostate cancer (CRPC).. <i>Journal of Clinical Oncology</i> , 2016, 34, e16539-e16539.	1.6	1
35	Phase II study of olaparib (without ADT) in men with high-risk biochemically-recurrent prostate cancer following prostatectomy, with integrated biomarker analysis.. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS386-TPS386.	1.6	1
36	RESTORE: A single-arm, open-label phase II trial of bipolar androgen therapy (BAT) in men with metastatic castration resistant prostate cancer (mCRPC) – A comparison of post-abiraterone (Abi) versus post-enzalutamide (Enza) patients (Pts).. <i>Journal of Clinical Oncology</i> , 2020, 38, 5576-5576.	1.6	1

#	ARTICLE	IF	CITATIONS
37	Early discontinuation of abiraterone acetate/prednisone (AA/P) in localized prostate cancer.. Journal of Clinical Oncology, 2022, 40, e17003-e17003.	1.6	1
38	Magnetite-PLGA Microparticles for Oral Delivery of Insulin. Materials Research Society Symposia Proceedings, 2005, 873, 1.	0.1	0
39	Navigating an Optimal Treatment Course for Advanced Kidney Cancer. Oncology, 2021, 35, 308-309.	0.5	0
40	Can patients with advanced malignancy and poor performance status benefit from nivolumab plus ipilimumab as a palliative treatment?. Journal of Clinical Oncology, 2021, 39, 12028-12028.	1.6	0
41	Abstract 1422: Neuropilin-2, a potential target against neuroendocrine like therapy resistant prostate cancer. , 2021, , .		0
42	Visceral metastases on abiraterone vs. placebo: A post-hoc analysis of mode of radiographic progression in COU-AA-302.. Journal of Clinical Oncology, 2018, 36, 194-194.	1.6	0
43	Anticipating the Next Challenging Clinical Dilemmas in Prostate Cancer. JCO Oncology Practice, 2020, 16, 791-792.	2.9	0